Bluejay Diagnostics secures $8.5M private placement, with potential $15.1M upside via warrants
What's the deal? Bluejay DiagnosticsDealroom has a profile for this one. Try Dealroom →, a medical diagnostics company, has secured $8.5M through a private placement. The deal could grow to $15.1M if series G and H warrants are fully exercised.
The financing includes 3,655,917 shares of common stock and corresponding warrants with an exercise price of $2.075 per share. The warrants are immediately exercisable and valid for five years.
Bluejay plans to use the funds for FDA approval-related clinical studies and other R&D activities, with a focus on bringing its IL-6 testing product to market. The capital should extend the company's cash runway into Q1 2027.
Why now? The company needs funding to advance its interleukin-6 (IL-6) diagnostic test through the regulatory process. Clinical studies required for FDA clearance are capital-intensive, and the financing gives Bluejay a roughly two-year window to hit key milestones.
What could go wrong? The full $15.1M depends on warrant holders choosing to exercise — which hinges on the stock trading above the $2.075 strike price. If shares underperform, Bluejay may be limited to the initial $8.5M.
FDA approval is never guaranteed. Clinical studies could produce unfavourable results, face delays, or require additional capital beyond what this round provides.
The securities were issued under a Section 4(a)(2) exemption and remain unregistered, which limits liquidity for investors and signals the early-stage nature of the raise.
The signal: Bluejay Diagnostics sits at the early growth stage in a point-of-care diagnostics market that continues to attract capital despite a challenging environment for small-cap medtech. The warrant-heavy structure — where nearly half the potential raise depends on future stock performance — has become a familiar playbook for pre-revenue diagnostics companies balancing dilution concerns against the high cost of FDA clinical studies. Whether Bluejay can convert its IL-6 platform into a cleared product before its Q1 2027 cash runway expires will be the real test of this bet.
Read more: Intellectia.AI
